ClinicalTrials.Veeva

Menu

Search for Biomarkers of Infection and Inflammation in Patients With Acute Stroke. (IBIS)

J

Jakob Ström

Status

Active, not recruiting

Conditions

Stroke, Acute
Pneumonia, Bacterial

Study type

Observational

Funder types

Other

Identifiers

NCT03812666
2018/288 (Other Identifier)
247991

Details and patient eligibility

About

This study will look for new biomarkers of infection and evaluate current biomarkers of infection in stroke patients. Patients with acute stroke will be monitored with daily blood samples for seven days and by clinical examination to detect infections for 10 days.

Full description

Rationale: Stroke is one of the leading causes of death globally, and infections after stroke contribute to a large part of the stroke-related mortality. The current study, which has a prospective, observational design, constitutes the second phase out of four in the Inflammatory Biomarkers In Stroke (IBIS) project, of which the overall goal is to enable early treatment of post-stroke infections.

Aim: To develop a combined clinical and molecular biological signature for early detection of pneumonia in patients with stroke.

Design: Prospective nested case control study

Methods:Patients (n=200) with acute stroke will be monitored with clinical examinations for ten days and by daily blood samples for seven days. When cases of pneumonia have been established, samples and examination results from days preceding overt pneumonia will be compared to samples from similar patients that did not develop pneumonia.

Outcome: Using proteomic and metabolomic methods, novel markers of upcoming pneumonia after stroke will be sought. Such laboratory markers will be combined with current biomarkers (such as C-reactive protein and procalcitonin) and data from clinical examinations, with the aim of constructing a biological signature that enables early detection of pneumonia.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptoms and radiology consistent with acute cerebral infarction or atraumatic intracerebral hemorrhage.
  • National Institutes of Health Stroke Scale (NIHSS) ≤5; mild stroke (n=25), NIHSS ≤10 and ≥ 6; moderate stroke (n=25) or NIHSS ≥ 11; severe stroke (n=150)
  • Onset of symptoms less than 48 hours before first study blood sampling.

Exclusion criteria

  • Symptoms and radiology consistent with acute cerebral infarction but full reversal of symptoms within 24 hours of onset. (i.e. transient ischemic attack, TIA)
  • Hemoglobin less than 90 g/l.
  • Ongoing inflammatory disease, such as rheumatoid arthritis or active inflammatory bowel disease.
  • Inability to undergo MRI scan (only patients with NIHSS ≤10 will be excluded by this criteria)

Trial design

200 participants in 3 patient groups

Severe stroke
Description:
Patients with severe (defined as NIHSS score of \> 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
Moderately stroke
Description:
Patients with moderately severe (defined as NIHSS score of \> 5 but \< 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
Mild stroke
Description:
Patients with mild (defined as NIHSS score of \<6) acute stroke, either ischemic or hemorrhagic. (n= 25)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems